🇺🇸 ClinicalTrials.govClinicalTrials.gov · 试验状态变更Doubao · 实盘不做把握 8/10不做原因:风险收益比不佳
北京时间·源无时间·以抓取为准·⟳ 抓取 20:13:34·⚡ 决策 10-21 20:16:27 +2m53s·5.9 天前
艾伯维Livmoniplimab联合Budigalimab中国肝癌Ⅰ期试验状态变更：仅约20人入组的早期安全性试验，无疗效数据，无可交易催化
事件为政府登记平台的早期临床试验状态更新：约20名受试者的Ⅰ期安全性导入+剂量扩展，无疗效数据、无审批、无金额或里程碑，唯一直接可交易主体是超大市值的艾伯维，增量相对其约3000亿美元市值完全不具materiality，且对应中国登记CTR20242999已显示主动终止，不构成任何正期望方向，故回避。
📄 原文ClinicalTrials.gov · 试验状态变更↗ 原文
Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority o…
不做 AbbVie Inc.（艾伯维）（ABBV.US）
约20人入组的中国Ⅰ期安全性/剂量扩展试验状态更新，无疗效、无审批、无金额，对约3000亿美元市值的艾伯维不具materiality，方向与edge均不成立；中国对应登记CTR20242999且已主动终止，不构成做多或可交易做空催化。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
NCT06487559是艾伯维livmoniplimab+budigalimab在中国约20名肝癌患者中的早期安全性/剂量扩展试验状态变更，无疗效或商业增量；对超大市值艾伯维不具materiality，无值得交易的方向。
消息传播链
- 政府临床试验登记平台对NCT06487559发布状态变更，研究为livmoniplimab+budigalimab中国肝癌Ⅰ期（安全性导入+剂量扩展，约20人、15中心），无疗效或商业结果。
主要风险
- 若状态实为终止/失败（中国对应登记CTR20242999显示主动终止），方向可能偏负面，但因资产早期、样本极小且ABBV体量巨大，同样不具可交易量级。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-21 · 影响 invalidates
未发现任何疗效读数、监管批准或商业里程碑；仅早期安全性/剂量扩展设计与一条中国对应登记主动终止，无做多依据。
检索:livmoniplimab budigalimab HCC phase data readout approval milestone 原文 ↗
先例如何影响了这次决策
对本次决策的影响:确认无需交易：不产生ENTER腿，也不支持做空
方向:无可对照先例；早期、小规模、无数据的临床试验登记状态变更对超大市值药企普遍无定价影响，方向不确立
涨幅量级:无高相似对齐先例，且事件不具materiality，不据以设定任何止盈止损
形态:不适用
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 3,172 ms
{"result": "search_processed_events:agent query=`budigalimab hcc china trial status change | livmoniplimab budigalimab hepatocellular carcinoma nct06487559 | livmoniplimab 肝癌 临床试验 中国`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、22646 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正 - web_search 成功 doubao_search · 1,774 ms
豆包搜索结果（原始查询:livmoniplimab budigalimab hepatocellular carcinoma NCT06487559 sponsor；API SearchType:web） - web_search 成功 doubao_search · 1,751 ms
豆包搜索结果（原始查询:livmoniplimab 是什么公司 研发 肝癌；API SearchType:web）
原文全文
展开原文 · 1,621 字
Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease. The purpose of this study is to assess adverse events and how livmoniplimab in combination with budigalimab moves through the body in adult Chinese participants with Locally Advanced or metastatic Child-Pugh A Hepatocellular Carcinoma (HCC).
Livmoniplimab is an investigational drug being developed for the treatment of HCC. There are 2 stages to this study. Stage 1 is a safety run-in. There are 2 treatment arms in stage 1 and participants will receive escalating doses of Livmoniplimab in combination with budigalimab (fixed dose). Stage 2 is dose expansion. There are 2 treatment arms in stage 2 and participants will receive Livmoniplimab in combination with budigalimab in multiple doses. Approximately 20 adult participants will be enrolled in the study across 15 sites in China.
In part 1 (dose escalation), participants will be intravenously infused with escalating doses of livmoniplimab in combination with budigalimab every 3 weeks. In part 2 (dose expansion), participants will be intravenously infused with livmoniplimab in combination with budigalimab in multiple doses every 3 weeks. The estimated duration of the study is up to 2 years.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Livmoniplimab is an investigational drug being developed for the treatment of HCC. There are 2 stages to this study. Stage 1 is a safety run-in. There are 2 treatment arms in stage 1 and participants will receive escalating doses of Livmoniplimab in combination with budigalimab (fixed dose). Stage 2 is dose expansion. There are 2 treatment arms in stage 2 and participants will receive Livmoniplimab in combination with budigalimab in multiple doses. Approximately 20 adult participants will be enrolled in the study across 15 sites in China.
In part 1 (dose escalation), participants will be intravenously infused with escalating doses of livmoniplimab in combination with budigalimab every 3 weeks. In part 2 (dose expansion), participants will be intravenously infused with livmoniplimab in combination with budigalimab in multiple doses every 3 weeks. The estimated duration of the study is up to 2 years.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
40b403e5e2· 2026-10-21 20:16 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前